Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale

Michael Hawkes, Robert Opika Opoka, Sophie Namasopo, Christopher Miller, Andrea L. Conroy, Lena Serghides, Hani Kim, Nisha Thampi, W. Conrad Liles, Chandy C. John, Kevin C. Kain

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

We hypothesize that supplemental inhaled nitric oxide (iNO) will improve outcomes in children with severe malaria receiving standard antimalarial therapy. The rationale for the hypothesized efficacy of iNO rests on: (1) biological plausibility, based on known actions of NO in modulating endothelial activation; (2) pre-clinical efficacy data from animal models of experimental cerebral malaria; and (3) a human trial of the NO precursor l-arginine, which improved endothelial function in adults with severe malaria. iNO is an attractive new candidate for the adjunctive treatment of severe malaria, given its proven therapeutic efficacy in animal studies, track record of safety in clinical practice and numerous clinical trials, inexpensive manufacturing costs, and ease of administration in settings with limited healthcare infrastructure. We plan to test this hypothesis in a randomized controlled trial (ClinicalTrials.gov Identifier: NCT01255215).

Original languageEnglish (US)
Pages (from-to)437-444
Number of pages8
JournalMedical Hypotheses
Volume77
Issue number3
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale'. Together they form a unique fingerprint.

Cite this